

## **SR Pharma plc ("the Company")**

### **Result of EGM**

**London 11 July 2005** – At the extraordinary general meeting (“EGM”) of the Company held earlier today, the single resolution put to shareholders was passed, approving the acquisition of Atugen AG that was first announced on 21 June 2005.

The 22,820,736 SR Pharma shares being issued as consideration to the Atugen shareholders will be admitted to trading on AIM tomorrow, 12 July 2005, at which point, the acquisition of approximately 96% of the issued share capital of Atugen by the Company will be complete. It is intended that the minority shareholdings in Atugen will be acquired by the Company in due course. Following admission of the enlarged share capital to trading on AIM, there will be 46,706,450 Ordinary Shares of 1p each in SR Pharma in issue.

Following today’s EGM, Jeremy Curnock Cook, Dr David U’Prichard and Professor Bernd Wetzel have been appointed as Non-executive Directors of SR Pharma with effect from Admission.

Further information:

Melvyn Davies  
Company Secretary  
SR Pharma plc

Tel: 020 7307 1620